Nalbuphine indications

For the complete or partial reversal of narcotic depression, including respiratory depression, induced by opioids including natural and synthetic narcotics, propoxyphene, methadone, nalbuphine, butorphanol, and pentazocine. Also indicated for the diagnosis of suspected acute opioid overdosage. 

Nalbuphine, a narcotic agonist-antagonist (10 mg in adult administered SC, IM, or IV every 3 to 6 hours) is indicated for the relief of moderate to severe pain, for preoperative analgesia, as a supplement to balanced analgesia and to surgical anesthesia, and for obstetrical analgesia during labor and delivery. 

Nalbuphine is indicated for the treatment of moderate to severe somatic and visceral pain. Additional indications include its use as a component of balanced anesthesia, treatment of pain associated with labor... 

Clinically, butorphanol has been evaluated in normal volunteers for safety and tolerance both orally and parenterally. Single intramuscular doses ranging from 0.1 to 20 mg were studied. There was no Indication of hallucinogenic activity even in one volunteer who received the 20 mg dose Butorphanol and nalbuphine 231 have been tested clinically for analgesia parenterally and found to be approximately 10 times morphine and equlpotent to morphine respectively. 

---